Dr Ian Chau speaks with ecancer about his CheckMate 648 study, comparing Nivolumab (NIVO) + Ipilimumab (IPI) or NIVO + chemotherapy vs chemo alone as first line (1L) treatment for advanced esophageal squamous-cell carcinomas (ESCC), which is the largest randomised control trial conducted in this disease setting.
He begins by explaining that 970 patients were allocated into three different treatment groups (NIVO + IPI, NIVO + chemo, chemo alone) with the primary end point of the study using the biomarker specified tumour PDL1 expression of 1% or more and used both overall survival and progression-free survival as the primary end points.
He then goes on to say that the base-line characteristics of patients were well balanced across all three treatment arms. Just under half of the patients were PDL1 expression positive by 1% or more. A highly statistically significant improvement was found in overall-survival in favour of NIVO + chemo vs chemo alone and a statistically significant survival benefit in favour of NIVO + IPI vs chemo alone.
Dr Chau concludes by talking about how this study will impact the future treatment of ESCC explaining that there are now two new treatment options including a chemotherapy-free option.
Read more on the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.